CCR4 and synovial sarcoma: Despite the progress made in implementing therapies for SS, such as targeted therapies, including monoclonal antibodies with long-term responses (i.e., mogamulizumab, directed against CCR4, which has demonstrated a substantial extension in progression-free survival) [20,21,22], none of the existing treatments are curative.